Preoperative Neck Ultrasonographic Mapping for Persistent/Recurrent Papillary Thyroid Cancer
- 21 October 2004
- journal article
- research article
- Published by Wiley in World Journal of Surgery
- Vol. 28 (11) , 1110-1114
- https://doi.org/10.1007/s00268-004-7636-5
Abstract
Surgical resection of persistent/recurrent (P/R) papillary thyroid cancer (PTC), when localized to the neck, is generally recommended; however, its impact on the course of the disease is not clear. We introduced a new technique in the form of preoperative neck ultrasonographic mapping (US-M) to improve the outcome of the surgical resection of P/R PTC. A total of 19 patients had undergone regional (central, lateral, or both) neck dissection before introducing the current technique (group 1, or G1), and 26 patients (group 2, or G2) had limited lymph node resection guided by US-M with findings accurately plotted on a standard diagram. All of the operations were performed by a single surgeon. The surgical outcomes of the two groups were compared. The resected lesions were positive for PTC in 17 patients (89.5%) in G1 and in 25 patients (96.2%) in G2. In G2, the intraoperative findings exactly matched the US-M in 23 patients (88.5%). Postoperatively, neck US became negative in 50% in G1 and in 83.3% in G2 (p = 0.02). Thyroglobulin (Tg) became undetectable in 37.5% in G1 and 52.3% in G2 (p = 0.37). Whole-body iodine scans (WBS) became negative in one of six patients (16.7%) in G1, and in three of four patients (75%) in G2, (p = 0.06). After a mean follow-up of 23.8 ± 7.1 months in G1 and 9.8 ± 4.7 months in G2, 6 patients (31.6%) in G1 and 15 patients (62.5%) in G2 were in remission (p = 0.04), whereas the disease persisted in 13 cases (68.4%) in G1 and 9 (37.5%) in G2 (p = 0.04). In conclusion, US-M improved the surgical outcome, as evidenced by the postoperative US, Tg, and WBS findings and the higher remission rate for the G2 patients than for the G1 patients.Keywords
This publication has 37 references indexed in Scilit:
- Lack of Impact of Radioiodine Therapy in Tg-Positive, Diagnostic Whole-Body Scan-Negative Patients with Follicular Cell-Derived Thyroid CancerJournal of Clinical Endocrinology & Metabolism, 2002
- Outcome of Differentiated Thyroid Cancer with Detectable Serum Tg and Negative Diagnostic 131I Whole Body Scan: Comparison of Patients Treated with High 131I Activities Versus Untreated PatientsJournal of Clinical Endocrinology & Metabolism, 2001
- Current Approaches to Primary Therapy for Papillary and Follicular Thyroid CancerJournal of Clinical Endocrinology & Metabolism, 2001
- Combination of Radioiodine (131I) and Probe-Guided Surgery for Persistent or Recurrent Thyroid CarcinomaJournal of Clinical Endocrinology & Metabolism, 1998
- Papillary and Follicular Thyroid CarcinomaNew England Journal of Medicine, 1998
- 131I Treatment of 131I Negative Whole Body Scan, and Positive Thyroglobulin in Differentiated Thyroid Carcinoma: What Is Being Treated?Thyroid®, 1997
- Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. American Thyroid AssociationArchives of internal medicine (1960), 1996
- Treating high thyroglobulin with radioiodine: a magic bullet or a shot in the dark?Journal of Clinical Endocrinology & Metabolism, 1995
- Recurrent Thyroid Cancer Role of Surgery Versus Radioactive Iodine (I131)Annals of Surgery, 1994
- Surgical reintervention for differentiated thyroid cancerBritish Journal of Surgery, 1993